Completed Phase 1b/2a trial of VTP-300 met its primary and secondary endpoints
VTP-300 is the first antigen-specific immunotherapy shown to induce sustained reductions in Hepatitis B surface antigen (HBsAg)
Results will be presented at the upcoming European Association for the Study of the Liver (EASL) Congress in June
Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company focused on the development of novel T cell immunotherapeutics designed to use the power of the immune system to potentially treat and cure chronic infectious diseases, autoimmune diseases and cancer, today announced positive topline final data from the HBV002 study (NCT04778904), a Phase 1b/2a clinical trial of VTP-300 in people with chronic Hepatitis B (HBV) infection.
The completed trial, which included 55 patients with chronic hepatitis B, supported the generally favorable tolerability profile previously reported with VTP-300, with no incidents of VTP-300-related Grade 3 adverse events or product-related serious adverse events following study dosing. VTP-300 was observed to induce meaningful, sustained reductions of Hepatitis B surface antigen (HBsAg) in patients with chronic HBV. Declines were most prominent in patients with lower baseline HBsAg. The final results of the immunology assays are currently being analyzed and the full data, including tolerability and immunogenicity results, will be presented at the upcoming EASL Congress, June 21-24, 2023.
https://finance.yahoo.com/news/vaccitech-announces-positive-topline-final-120000766.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.